Biopharma Patent Disputes: Upheaval Likely As US Supreme Court Limits Litigation Venue
Executive Summary
Decision requiring suits to be filed in state where defendant is incorporated may deter consolidation of ANDA suits and increase venue fights; Court to hear challenge to PTAB inter partes review process.
You may also be interested in...
Judge Kavanaugh May Be Good US Supreme Court Pick For Pharma
Supreme Court nominee may side with biopharma companies in agency disputes, but it's unclear how he will rule on patent and product liability cases scheduled for review next term.
He's Handled More ANDA Cases Than Anyone, And Now He's Retiring: Judge Sleet Reflects On His Career
In an interview with the Pink Sheet, Delaware District Judge Sleet discusses patent reform fallout and major issues facing district courts.
He's Handled More ANDA Cases Than Anyone, And Now He's Retiring: Judge Sleet Reflects On His Career
In an interview with the Pink Sheet, Delaware District Judge Sleet discusses patent reform fallout and major issues facing district courts.